NCT07444723 2026-03-18
Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors
National Institutes of Health Clinical Center (CC)
Phase 2/3 Not yet recruiting
Clinical Trials
23 trialsNCT06943755 2026-02-27
STELLAR-311
Exelixis
Phase 2/3 Recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT06100367 2025-12-02
11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours
Changi General Hospital
Phase 2/3 Active not recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT07165886 2025-09-10
Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2/3 Recruiting
NCT06398444 2025-09-05
A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
Sinotau Pharmaceutical Group
Phase 2/3 Active not recruiting
NCT06855095 2025-03-03
ATSA
The Netherlands Cancer Institute
Phase 2/3 Recruiting
NCT02873559 2024-05-29
PROGRESS
University Hospital, Gentofte, Copenhagen
Phase 2/3 Completed
NCT01398085 2024-05-08
IoN
University College, London
Phase 2/3 Active not recruiting
NCT05749289 2024-03-29
Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3 Recruiting
NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
NCT00442533 2023-04-03
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Radio Isotope Therapy of America
Phase 2/3 Completed
NCT03590119 2022-11-08
LUTIA
UMC Utrecht
Phase 2/3 Completed
NCT02608203 2022-10-14
GEP-NOC
Assistance Publique Hopitaux De Marseille
Phase 2/3 Completed
NCT04552847 2022-02-17
Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
Universitaire Ziekenhuizen KU Leuven
Phase 2/3 Completed
NCT01744249 2021-02-02
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Grupo Espanol de Tumores Neuroendocrinos
Phase 2/3 Unknown
NCT04244708 2020-01-28
The Effect of Chemoradiotherapy in Patients With Refractory Pituitary Adenomas
Peking Union Medical College Hospital
Phase 2/3 Unknown
NCT03992911 2019-06-20
Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma
Peking University
Phase 2/3 Unknown
NCT02586337 2019-05-21
Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown
NCT01379183 2016-03-21
Using Magnetic Resonance (MR) to Understand the Effect of Erythromycin on Bowel Motility
Mayo Clinic
Phase 2/3 Completed
NCT00997594 2015-04-28
Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation
Mie University
Phase 2/3 Completed
NCT00507429 2014-06-09
FACT
Mateon Therapeutics
Phase 2/3 Terminated